Physician profile
Howard A Aronow
NPI 1982629564
$3,942.10
in general payments reported to CMS, 2019-2025
22 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.62 · 2020: $151 · 2021: $573 · 2022: $1,799 · 2023: $362 · 2024: $348 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.97 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,652.82 | 2022 | |
| Pfizer INC. | $670.82 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $210.25 | 2020-2021 | |
| Harmony Biosciences LLC | $152.77 | 2022-2023 | Wakix |
| Lilly USA, LLC | $151.75 | 2020-2025 | Amyvid, Kisunla |
| Jazz Pharmaceuticals INC. | $150.00 | 2025 | |
| Glaxosmithkline, LLC. | $139.36 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $124.66 | 2024-2025 | Ingrezza |
| Janssen Products, LP | $99.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $95.76 | 2024-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Theratechnologies INC. | $81.24 | 2021 | |
| Acorda Therapeutics, INC | $66.85 | 2020 | |
| Adamas Pharmaceuticals, INC. | $57.64 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $53.23 | 2025 | Austedo Xr |
| Biogen, INC. | $47.75 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.44 | 2022 | |
| Mdd US Operations, LLC | $39.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Lundbeck LLC | $27.55 | 2025 | Vyepti |
| Viiv Healthcare Company | $19.52 | 2019 | |
| Janssen Biotech, INC. | $14.28 | 2021 | |
| Gilead Sciences, INC. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Aronow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.